维奈克拉联合柔红霉素和阿糖胞苷治疗新诊断急性髓系白血病:1b期研究结果
这项1b期研究评估了维奈克拉联合柔红霉素和阿糖胞苷(7+3方案)治疗新诊断急性髓系白血病的安全性和疗效。34例患者接受维奈克拉递增持续时间(8、11或14天)治疗,复合完全缓解率达85.3%,86.2%的患者可测量残留病阴性。中位随访9.6个月时,缓解持续时间、无事件生存期和总生存期均未达到。
要点
- 维奈克拉(400 mg)联合7+3化疗在新诊断急性髓系白血病中安全有效,可实现可测量残留病阴性缓解。
- 复合完全缓解率为85.3%,86.2%的患者可测量残留病阴性,缓解跨越所有欧洲白血病网2022风险类别。
- 不良事件包括发热性中性粒细胞减少(100%)、脓毒症(29%)和肠结肠炎(23.5%),但无诱导死亡。
核心结论
- 维奈克拉(400 mg)联合7+3化疗在新诊断急性髓系白血病中安全有效,可在所有持续时间组中实现可测量残留病阴性缓解。
- 维奈克拉剂量优化正在该试验的扩展阶段进行探索。
- 未来需要多中心研究来证实本研究发现。
研究设计与样本
- 1b期研究,共纳入34例新诊断急性髓系白血病患者,中位年龄59岁,62%为非白人。
- 患者接受维奈克拉递增持续时间(8、11或14天)联合柔红霉素和阿糖胞苷治疗。
- 试验在clinicaltrials.gov注册,注册号为NCT05342584。
主要发现
- 不良事件包括发热性中性粒细胞减少(100%)、脓毒症(29%)和肠结肠炎(23.5%),但无诱导死亡。
- 中性粒细胞(>1.0 × 10³/μL)和血小板(>100 × 10³/μL)的中位恢复时间均小于30天。
- 复合完全缓解率为85.3%,86.2%的患者可测量残留病阴性。
- 缓解跨越所有欧洲白血病网2022风险类别。
- 中位随访9.6(范围2-20)个月时,中位缓解持续时间、无事件生存期和总生存期均未达到。
局限性
- 未来需要多中心研究来证实本研究发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax (Ven), when combined with intensive chemotherapy, shows promise for untreated acute myeloid leukemia (AML), but its integration with the 7+3 regimen remains underexplored. In a phase 1b study, we assessed the safety and efficacy of Ven with daunorubicin and cytarabine in patients with newly diagnosed AML. A total of 34 patients (median age, 59 years; 62% non-White) received Ven at escalating durations (8, 11, or 14 days). Adverse events included febrile neutropenia (100%), sepsis (29%), and enterocolitis (23.5%), but there were no induction deaths. The median recovery times for neutrophils (>1.0 × 103/μL) and platelets (>100 × 103/μL) were less than 30 days. Composite complete remission was achieved in 85.3% of patients, and 86.2% were negative for measurable residual disease (MRD). Responses spanned all European Leukemia Net 2022 risk categories. With a median follow-up of 9.6 (2-20) months, the median duration of response, event-free survival, and overall survival were not reached. Ven (400 mg), when combined with 7+3 chemotherapy, was safe and effective in achieving MRD-negative remissions across all durations. Ven dose optimization is being explored in the expansion phase of this trial. Future multicenter studies should confirm our findings. This trial was registered at clinicaltrials.gov as #NCT05342584.
引用
- Mantzaris I, Goldfinger M, Uriel M, et al. Venetoclax plus daunorubicin and cytarabine for newly diagnosed acute myeloid leukemia: results of a phase 1b study. Blood. 2025. PMID: 39919267. doi:10.1182/blood.2024026700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。